DBV Technologies S.A. (NASDAQ:DBVT) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Posted by Geri Gentry on May 18th, 2026

DBV Technologies S.A. (NASDAQ:DBVT – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the nine analysts that are covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and two have given a strong buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $40.25.

Several equities research analysts have recently commented on the company. Citizens Jmp upped their price target on DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Friday, May 1st. Citigroup reiterated an “outperform” rating on shares of DBV Technologies in a research report on Friday, May 1st. Wall Street Zen raised DBV Technologies from a “sell” rating to a “hold” rating in a report on Saturday, May 2nd. Finally, Guggenheim reaffirmed a “buy” rating and set a $51.00 price objective on shares of DBV Technologies in a research note on Monday, May 4th.

Read Our Latest Analysis on DBVT

Institutional Trading of DBV Technologies

A number of hedge funds have recently added to or reduced their stakes in the business. Artisan Partners Limited Partnership boosted its stake in DBV Technologies by 6,273.4% in the 4th quarter. Artisan Partners Limited Partnership now owns 3,309,055 shares of the company’s stock worth $63,435,000 after buying an additional 3,257,135 shares during the last quarter. Vivo Capital LLC raised its holdings in shares of DBV Technologies by 133.4% during the 4th quarter. Vivo Capital LLC now owns 2,461,626 shares of the company’s stock valued at $47,189,000 after buying an additional 1,407,120 shares during the period. Siren L.L.C. purchased a new stake in shares of DBV Technologies during the 4th quarter valued at about $35,606,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of DBV Technologies during the 2nd quarter valued at about $9,659,000. Finally, MPM Bioimpact LLC purchased a new stake in shares of DBV Technologies during the 2nd quarter valued at about $9,649,000. 71.74% of the stock is owned by institutional investors and hedge funds.

DBV Technologies Stock Performance

DBVT stock opened at $19.65 on Monday. The company has a market capitalization of $1.16 billion, a P/E ratio of -4.41 and a beta of -0.96. DBV Technologies has a twelve month low of $7.53 and a twelve month high of $26.18. The business has a 50 day simple moving average of $20.51 and a 200-day simple moving average of $19.14.

DBV Technologies (NASDAQ:DBVT – Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.42). The firm had revenue of $0.90 million during the quarter, compared to analyst estimates of $1.11 million. DBV Technologies had a negative net margin of 2,895.37% and a negative return on equity of 129.88%. Research analysts predict that DBV Technologies will post -0.47 EPS for the current fiscal year.

About DBV Technologies

(Get Free Report)

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.